Key Insights

Highlights

Success Rate

50% trial completion

Treatment Research

4 treatments under study, led by Multifaceted Knowledge Translation Intervention

Research Leaders

7 sponsors active, led by University of Toronto

Related Conditions

Often studied with 13 related conditions

Clinical Risk Assessment

Based on trial outcomes

High Risk

Score: 85/100

Termination Rate

20.0%

1 terminated out of 5 trials

Success Rate

50.0%

-36.6% vs benchmark

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 1 completed with results

Key Signals

50% success

Data Visualizations

Phase Distribution

2Total
Not Applicable (2)

Trial Status

Recruiting1
Terminated1
Completed1
Unknown1
Withdrawn1

Trial Success Rate

50.0%

Benchmark: 86.6%

Based on 1 completed trials

Clinical Trials (5)

Showing 5 of 5 trials
NCT04889326Withdrawn

Collection of the Thrombo-VaxCov Cohort

NCT04446832Recruiting

VACcination of LIver Transplantation Candidates

NCT03966391Not ApplicableCompletedPrimary

Effectiveness of CARD for Improving School-Based Immunizations

NCT05186571Unknown

Myopericarditis After Messenger Ribonucleic Acid (mRNA) COVID-19 Vaccination in Children 5-11 Years Old

NCT03966300Not ApplicableTerminated

Improving the School Vaccination Experience: What CARDs Are You Going to Play?

Showing all 5 trials

Research Network

Common Treatments

  • Multifaceted Knowledge Translation Intervention2
  • Retrospective Data And Biological Samples1
  • Pfizerbiontech Mrna Covid19 Vaccination1
  • Vaccine Immunogenicity1

Active Sponsors

  • University of Toronto2
  • Ministry of Education, Denmark1
  • Copenhagen University Hospital, Rigshospitalet1
  • Hospices Civils de Lyon1
  • University Hospital, Lille1

Top Investigators

Related Conditions

  • Vaccine Adverse Reaction2
  • Fear2
  • Thrombocytopenia1
  • Cirrhosis1
  • Myocarditis1

Activity Timeline